Breast Cancer Research and Treatment

, Volume 132, Issue 2, pp 545–553 | Cite as

The prognostic significance of B lymphocytes in invasive carcinoma of the breast

  • S. M. A. Mahmoud
  • A. H. S. Lee
  • E. C. Paish
  • R. D. Macmillan
  • I. O. Ellis
  • A. R. Green
Preclinical Study


Although the favourable role of T lymphocyte populations in different tumour types is established, that of B cells is still a matter of debate and needs further clarification. The presence of tumour-infiltrating B cells may represent an antibody response against breast tumour antigens. We used immunohistochemistry to investigate the density and localisation of B lymphocytes infiltrating 1470 breast tumours and to identify any prognostic significance and relationship to various clinicopathological factors. Higher numbers of CD20+ cells were found in the stroma away from the carcinoma (mean 12 cells) compared with either intratumoural or adjacent stromal compartments (mean 1 cell). The majority of tumours showed a diffuse pattern of B cells rather than aggregates. There was a positive correlation between higher numbers of total CD20+ B cells and higher tumour grade (r s = 0.20, P < 0.001), ER and PgR negativity (P < 0.001), and basal phenotype (P < 0.001) subclass. In univariate survival analysis, higher total number of infiltrating CD20+ cells, irrespective of location, was associated with significantly better BCSS (P = 0.037) and longer DFI (P = 0.001). In multivariate analysis, total CD20+ B cell count (HR = 0.75, 95% CI = 0.58–0.96 for BCSS and HR = 0.72, 95% CI = 0.58–0.89, for DFI), tumour size, nodal stage, grade, vascular invasion, HER-2 status, and total CD8+ T cell count were independently associated with outcome. This suggests that humoral immunity, in addition to the cell mediated immunity, may be important in breast cancer. This should be considered in breast cancer immunotherapy and vaccine strategies.


CD20 Immunohistochemistry Breast cancer B lymphocytes Humoral immunity 


  1. 1.
    Bouaziz JD, Yanaba K, Venturi GM, Wang Y, Tisch RM, Poe JC et al (2007) Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci USA 104(52):20878–20883PubMedCrossRefGoogle Scholar
  2. 2.
    Crawford A, Macleod M, Schumacher T, Corlett L, Gray D (2006) Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J Immunol 176(6):3498–3506PubMedGoogle Scholar
  3. 3.
    Coughlin CM, Vance BA, Grupp SA, Vonderheide RH (2004) RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 103(6):2046–2054PubMedCrossRefGoogle Scholar
  4. 4.
    Schultz KR, Klarnet JP, Gieni RS, HayGlass KT, Greenberg PD (1990) The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia. Science 249(4971):921–923PubMedCrossRefGoogle Scholar
  5. 5.
    de Visser KE, Korets LV, Coussens LM (2005) De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7(5):411–423PubMedCrossRefGoogle Scholar
  6. 6.
    Houghton AN, Uchi H, Wolchok JD (2005) The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword. Cancer Cell 7(5):403–405PubMedCrossRefGoogle Scholar
  7. 7.
    Bernatsky S, Ramsey-Goldman R, Clarke A (2006) Malignancy and autoimmunity. Curr Opin Rheumatol 18(2):129–134PubMedCrossRefGoogle Scholar
  8. 8.
    Tomer Y, Sherer Y, Shoenfeld Y (1998) Autoantibodies, autoimmunity and cancer (review). Oncol Rep 5(3):753–761PubMedGoogle Scholar
  9. 9.
    Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, Gilks CB et al (2009) Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 4(7):e6412PubMedCrossRefGoogle Scholar
  10. 10.
    Dong HP, Elstrand MB, Holth A, Silins I, Berner A, Trope CG et al (2006) NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol 125(3):451–458PubMedGoogle Scholar
  11. 11.
    Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT (2008) Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 14(16):5220–5227PubMedCrossRefGoogle Scholar
  12. 12.
    Kuroda H, Tamaru J, Sakamoto G, Ohnisi K, Itoyama S (2005) Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast. Virchows Arch 446(1):10–14PubMedCrossRefGoogle Scholar
  13. 13.
    Hansen MH, Nielsen HV, Ditzel HJ (2002) Translocation of an intracellular antigen to the surface of medullary breast cancer cells early in apoptosis allows for an antigen-driven antibody response elicited by tumor-infiltrating B cells. J Immunol 169(5):2701–2711PubMedGoogle Scholar
  14. 14.
    Hansen MH, Nielsen H, Ditzel HJ (2001) The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci USA 98(22):12659–12664PubMedCrossRefGoogle Scholar
  15. 15.
    Lee AH, Happerfield LC, Bobrow LG, Millis RR (1997) Angiogenesis and inflammation in invasive carcinoma of the breast. J Clin Pathol 50(8):669–673PubMedCrossRefGoogle Scholar
  16. 16.
    Nzula S, Going JJ, Stott DI (2003) Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res 63(12):3275–3280PubMedGoogle Scholar
  17. 17.
    Coronella JA, Spier C, Welch M, Trevor KT, Stopeck AT, Villar H et al (2002) Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol 169(4):1829–1836PubMedGoogle Scholar
  18. 18.
    Lee AH, Happerfield LC, Millis RR, Bobrow LG (1996) Inflammatory infiltrate in invasive lobular and ductal carcinoma of the breast. Br J Cancer 74(5):796–801PubMedCrossRefGoogle Scholar
  19. 19.
    Tedder TF, Engel P (1994) CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 15(9):450–454PubMedCrossRefGoogle Scholar
  20. 20.
    Stashenko P, Nadler LM, Hardy R, Schlossman SF (1980) Characterization of a human B lymphocyte-specific antigen. J Immunol 125(4):1678–1685PubMedGoogle Scholar
  21. 21.
    Cragg MS, Walshe CA, Ivanov AO, Glennie MJ (2005) The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 8:140–174PubMedCrossRefGoogle Scholar
  22. 22.
    Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF et al (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116(3):340–350PubMedCrossRefGoogle Scholar
  23. 23.
    Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG et al (2006) Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 208(4):495–506PubMedCrossRefGoogle Scholar
  24. 24.
    Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403–410PubMedCrossRefGoogle Scholar
  25. 25.
    Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW (1992) Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 20(6):479–489PubMedCrossRefGoogle Scholar
  26. 26.
    Galea MH, Blamey RW, Elston CE, Ellis IO (1992) The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22(3):207–219PubMedCrossRefGoogle Scholar
  27. 27.
    Pinder SE, Ellis IO, Galea M, O’Rouke S, Blamey RW, Elston CW (1994) Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology 24(1):41–47PubMedCrossRefGoogle Scholar
  28. 28.
    McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23(36):9067–9072PubMedCrossRefGoogle Scholar
  29. 29.
    Camp RL, Charette LA, Rimm DL (2000) Validation of tissue microarray technology in breast carcinoma. Lab Invest 80(12):1943–1949PubMedCrossRefGoogle Scholar
  30. 30.
    Mahmoud SMA, Paish EC, Powe DG, Macmillan RD, Lee AHS, Ellis IO et al (2011) An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat 127(1):99–108Google Scholar
  31. 31.
    Rakha EA, El-Sheikh SE, Kandil MA, El-Sayed ME, Green AR, Ellis IO (2008) Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Pathol 39(6):857–865PubMedCrossRefGoogle Scholar
  32. 32.
    Mahmoud SMA, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AHS et al (2011) Tumor-infiltarting CD8+ lymphocytes predicts clinical outcome in breast cancer. J Clin Oncol 29(15):1949-1955Google Scholar
  33. 33.
    Cox DR (1972) Regression models and life-tables. J R Stat Soc Series B Stat Methodol 34(2):187–220Google Scholar
  34. 34.
    Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10(21):7252–7259PubMedCrossRefGoogle Scholar
  35. 35.
    Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL (2006) Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 66(10):5487–5494PubMedCrossRefGoogle Scholar
  36. 36.
    Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF et al (2004) Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203(2):661–671PubMedCrossRefGoogle Scholar
  37. 37.
    Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109(1):25–32PubMedCrossRefGoogle Scholar
  38. 38.
    Rakha EA, El-Rehim DA, Paish C, Green AR, Lee AH, Robertson JF et al (2006) Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 42(18):3149–3156PubMedCrossRefGoogle Scholar
  39. 39.
    Marsigliante S, Biscozzo L, Marra A, Nicolardi G, Leo G, Lobreglio GB et al (1999) Computerised counting of tumour infiltrating lymphocytes in 90 breast cancer specimens. Cancer Lett 139(1):33–41PubMedCrossRefGoogle Scholar
  40. 40.
    Naukkarinen A, Syrjanen KJ (1990) Quantitative immunohistochemical analysis of mononuclear infiltrates in breast carcinomas—correlation with tumour differentiation. J Pathol 160(3):217–222PubMedCrossRefGoogle Scholar
  41. 41.
    Stewart TH, Heppner GH (1997) Immunological enhancement of breast cancer. Parasitology 115(Suppl):S141–S153PubMedCrossRefGoogle Scholar
  42. 42.
    Rohrer JW, Barsoum AL, Dyess DL, Tucker JA, Coggin JH Jr (1999) Human breast carcinoma patients develop clonable oncofetal antigen-specific effector and regulatory T lymphocytes. J Immunol 162(11):6880–6892PubMedGoogle Scholar
  43. 43.
    Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL et al (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24(34):5373–5380PubMedCrossRefGoogle Scholar
  44. 44.
    Bilik R, Mor C, Hazaz B, Moroz C (1989) Characterization of T-lymphocyte subpopulations infiltrating primary breast cancer. Cancer Immunol Immunother 28(2):143–147PubMedCrossRefGoogle Scholar
  45. 45.
    Georgiannos SN, Renaut A, Goode AW, Sheaff M (2003) The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators. Surgery 134(5):827–834PubMedCrossRefGoogle Scholar
  46. 46.
    Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E et al (1992) Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 28A(4–5):859–864PubMedCrossRefGoogle Scholar
  47. 47.
    Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H et al (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68(13):5405–5413PubMedCrossRefGoogle Scholar
  48. 48.
    Lee AH, Gillett CE, Ryder K, Fentiman IS, Miles DW, Millis RR (2006) Different patterns of inflammation and prognosis in invasive carcinoma of the breast. Histopathology 48(6):692–701PubMedCrossRefGoogle Scholar
  49. 49.
    Lee AHS (2008) Inflammation and vascularity in carcinoma of the breast. University of Cambridge, CambridgeGoogle Scholar
  50. 50.
    Balch CM, Riley LB, Bae YJ, Salmeron MA, Platsoucas CD, von Eschenbach A et al (1990) Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg 125(2):200–205PubMedCrossRefGoogle Scholar
  51. 51.
    Lee YT, Sheikh KM, Quismorio FP Jr, Friou GJ (1985) Circulating anti-tumor and autoantibodies in breast carcinoma: relationship to stage and prognosis. Breast Cancer Res Treat 6(1):57–65PubMedCrossRefGoogle Scholar
  52. 52.
    Coronella-Wood JA, Hersh EM (2003) Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother 52(12):715–738PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • S. M. A. Mahmoud
    • 1
    • 2
  • A. H. S. Lee
    • 3
  • E. C. Paish
    • 3
  • R. D. Macmillan
    • 4
  • I. O. Ellis
    • 1
    • 3
  • A. R. Green
    • 1
  1. 1.Division of Pathology, School of Molecular Medical SciencesUniversity of Nottingham, Queen’s Medical CentreNottinghamUK
  2. 2.Clinical Pathology Department, Faculty of MedicineMansoura UniversityMansouraEgypt
  3. 3.Department of HistopathologyNottingham University Hospitals NHS TrustNottinghamUK
  4. 4.The Breast InstituteNottingham University Hospitals NHS TrustNottinghamUK

Personalised recommendations